Kronik hepatit B ve B+D kaynaklı sirozda, hepatoselüler karsinom gelişiminin öngörülmesinde ALBI ve PALBI skorlamalarının prediktif değeri

Yıl 2019, Cilt: 7 Sayı: 3, 172 - 179, 18.12.2019

Tolga Şahin , Alihan Oral

Öz

Amaç: Hepatoselüler karsinom (HCC), dünya
çapında kanser kaynaklı ölümlerin ikinci en yaygın nedenidir. HCC, çoğu olguda
sirotik karaciğer dokularında gelişir. HCC'nin teşhisinde ve tedavisinde yeni
gelişmeler olmasına rağmen, 5 yıllık sağkalım oranı halen % 12' nin altındadır.
Bu nedenle, erken tanı ve agresif yaklaşım, HCC tedavisi için en önemli nokta
haline gelmiştir. Bu çalışmanın amacı, kronik hepatit B ve kronik hepatit B + D
kaynaklı sirozda HCC gelişiminde albumin-bilirubin indeksi (ALBI) ve Platelet-albumin-bilirubin
indeksinin (PALBI) prediktivitelerinin değerlendirilmesidir.

Materyal
ve Metod: Çalışmaya 2004-2019
yılları arasında Demiroğlu Bilim Üniversitesi Tıp Fakültesi Gastroenteroloji
bölümüne başvuran kronik hepatit B ve kronik hepatit B + D ‘ye bağlı karaciğer
sirozu bulunan 331 hasta dahil edildi. Hastalar HCC olan ve olmayan hastalar olmak
üzere iki ana gruba ayrıldı. Hastaların demografik verileri ve vücut kitle
indeksleri istatistiksel olarak analiz edildi. Hastaların Child ve MELD
skorları ile laboratuvar bulguları gruplar için ayrı ayrı kaydedildi ve incelendi.
Ortalama ALBI ve PALBI değerleri her iki hasta grubu için ayrı ayrı hesaplandı.
Son aşamada HCC gelişimi ile ALBI ve PALBI arasındaki ilişki ve bu skorların
prediktif değerleri değerlendirildi.

Bulgular: Hastaların yaş ortalaması 51.3 ± 9.18,
ortalama ağırlığı 77.7 ± 13.08 kg, ortalama boyu 165 ± 18 cm, ortalama vücut
kitle indeksi (BKİ) ise 30.04 ± 11.65 idi. HCC grubu 115 hastadan ve HCC
olmayan siroz grubu 216 hastadan oluşmaktaydı. Ortalama ALBI ve PALBI skor
değerleri, HCC grubu hastalarda, HCC olmayan sirozlu hasta grubuna göre anlamlı
derecede düşüktü (p <0,001). Receiver operating characteristics (ROC)
analizi yapıldığında, eğri altındaki alan (AUC) ALBI skoru için 0.775 ve PALBI
skoru için 0.733 olarak saptandı.

Sonuç:
ALBI ve PALBI skorları HCC’ li hastalarda sağkalım ve prognozun
öngörülmesi amacı ile geliştirilmiştir. Çalışmamızda, ALBI ve PALBI skorlarının
HCC ‘de sağkalım ve prognoz tahimininin yanısıra, sirozlu hastalarda HCC
gelişimi öngörüsünde de kullanışlı belirteçler olabilecekleri sonucuna varıldı.

Anahtar Kelimeler

ALBI, PALBI, Hepatocellular carcinoma, Siroz

Kaynakça

• 1- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
• 2- Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015; 13: 2140–51.
• 3- El-Serag HB. Hepatocellular carcinoma. N. Engl.J. Med. 2011; 365: 1118-1127
• 4- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–4.
• 5- Forner A, Reig ME, De Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61–74.
• 6- Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918–28.
• 7- Gallo C. Capuano G, Daniele B, Gaeta GB, Perrone F, Pignata S. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751–5.
• 8- Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224–9.
• 9- Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009; 16: 453–63.
• 10- Perz JF, Armstrong GL, Farrington LA, Huntin YJ, Bell BP. The contributions of hepatitis B virüs and hepatitis C virüs infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;4:529-38.
• 11- Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458
• 12- Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013; 19:3944-54.
• 13- Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-53. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22.
• 14- Wang T, Liu M, Zheng SJ, Bian DD, Zhang JY, Yao J, et al. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma. World J Gastroenterol 2017 May 21; 23(19): 3496-3504.
• 15- Mathew S, Ali A, Abdel-Hafiz H, Fatima K, Suhail M, Archunan G, et al. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infect Genet Evol. 2014 Aug;26:327-39. doi: 10.1016/j.meegid.2014.06.014. Epub 2014 Jun 21.
• 16- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-70.
• 17- Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903.
• 18- Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12:1049-61.
• 19- Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol 2015; 33: 550–8.
• 20- Chan AW, Kumada T, Toyoda H, Tada T, Chong CC, Mo FK, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016; 31: 1300–6.
• 21- Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016; 31:1031–6.
• 22- Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, et al. PALBI - An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child’s Classification. In: The Liver Meeting. San Francisco, USA: American Association for the Study of Liver Diseases, 2015.
• 23- Chan AW, Chong CC, Mo FK, Wong J, Yeo W, Johnson PJ, et al. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2016 Oct;31(10):1766-1772. doi: 10.1111/jgh.13339.
• 24- Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, et al. Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatology Research 2017; 47: 731–741
• 25- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]
• 26- Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004-Nov;127(5 Suppl 1):S218–24.
• 27- Ho CHM, Chiang CL, Lee FAS, Choi HCW, Chan JCH, Yeung CSY, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin(ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). Oncotarget, 2018, Vol. 9, (No. 48), pp: 28818-28829.
• 28- Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology 32; (2017): 879–886.
• 29- Hansmann J, Evers MJ, Bui JT, Lokken RP, Lipnik AJ, Gaba RC, et al. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017 Sep;28(9):1224-1231.e2. doi: 10.1016/j.jvir.2017.05.020.
• 30- Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846.
• 31- Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One. 2019 May 2;14(5):e0216173. doi: 10.1371/journal.pone.0216173. eCollection 2019.
• 32- Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, et al. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019 May 1. pii: S1590-8658(19)30545-6. doi: 10.1016/j.dld.2019.04.006.
• 33- Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, et al. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol. 2019 Jun 27;11(6):542-552. doi: 10.4254/wjh.v11.i6.542.